Equities research analysts at Raymond James assumed coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a report issued on Monday,Briefing.com Automated Import reports. The brokerage set an "outperform" rating and a $45.00 price target on the stock. Raymond James' target price points to a potential upside of 29.46% from the company's previous close.
Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC started coverage on shares of Hinge Health in a research report on Monday. They issued a "buy" rating and a $47.00 price target for the company. Morgan Stanley initiated coverage on Hinge Health in a research report on Monday. They issued an "overweight" rating and a $46.00 target price for the company. Wall Street Zen raised Hinge Health to a "hold" rating in a research report on Monday, June 2nd. Evercore ISI assumed coverage on Hinge Health in a research report on Monday. They set an "outperform" rating and a $50.00 price objective for the company. Finally, Piper Sandler assumed coverage on Hinge Health in a research note on Monday. They set an "overweight" rating and a $41.00 target price on the stock. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.00.
View Our Latest Research Report on HNGE
Hinge Health Trading Down 0.7%
NYSE HNGE opened at $34.76 on Monday. Hinge Health has a 1 year low of $33.42 and a 1 year high of $43.80.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
